Loading clinical trials...

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

NCT04749563•IGC Pharma, LLC

View on ClinicalTrials.gov

Summary

A single center, randomized, placebo controlled multiple ascending dose study of IGC AD1 to evaluate safety and tolerability in subjects with dementia due to Alzheimer's Disease (AD).

Detailed Description

This is a phase I Multiple Ascending Dose (MAD) study to evaluate safety and tolerability of IGC-AD1 in subjects with AD. Twelve subjects will be enrolled. Three different ascending doses of the study product will be given: low, medium and high doses. Each dose will be given for 2 weeks, followed by a washout period of 4 days. Given the vulnerability of the population, a safety cohort of 3 patients (2 active, 1 placebo) will start every dose one day ahead of the rest of the patients and will be followed for 24 hours for the development of Adverse Events (AEs). Objective criteria will be set after the safety cohort is evaluated.

Eligibility

Age

60 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patient and/or study partner (relative) must provide a signed and dated Informed Consent form prior to any study procedures which will be discussed with the Study Coordinator.
•2. Provision of a letter from the Neurologist/Psychiatrist/Internal Medicine Physician certifying the diagnosis of Alzheimer's Dementia and patient's ability to consent. If patient is unable to consent, only the legal guardian/tutor of the patient could consent in his/her behalf. The guardian/tutor will be required to present the pertinent legal documentation.
•3. Must have a study partner who is able and willing to comply with all required study procedures.
•4. Patient should meet NIA-AA criteria for Alzheimer's disease, any stage.
•5. At least 3 months evolution of behavioral symptoms at screening visit.
•6. Negative drug screen, except for benzodiazepines if patient has been using them in stable doses for at least 3 months before screening.
•7. All medications used for behavioral symptoms should be in stable doses for at least 3 months before screening.
•8. All medications used for other conditions besides behavioral symptoms should be at stable doses for at least 30 days before screening.
•9. Women must be postmenopausal (defined as cessation of menses for at least 1 year) or surgically sterile (hysterectomy, oophorectomy or bilateral tubal ligation) at the time of screening.

Exclusion Criteria

•1. Prior adverse reaction to cannabinoids.
•2. Prior contraindication or allergy to any component of study product (IGC-AD1): melatonin, honey, curcumin, ethyl alcohol, vitamin-E TPGS, ascorbic acid, water, tween-80, and rutin.
•3. History of stroke, multiple sclerosis (MS), or epilepsy. History of gastrointestinal dysfunction not related to Alzheimer's disease (e.g., inflammatory bowel disease or gastrointestinal cancer)
•4. Any clinically relevant neurological disorder capable of producing a dementia syndrome including Parkinson's disease, stroke, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, and others.
•5. Other possible causes of dementia as: infections of the CNS (e.g. HIV, syphilis) or Creutzfeldt Jakob disease, subdural hematoma, communicating hydrocephalus, brain tumors, drug intoxication, alcohol intoxication, thyroid disease, parathyroid disease, and vitamin B12 or other deficiencies
•6. Use of contraindicated medication (see section 6).
•7. History of myocardial infarction, severe congestive heart failure, unstable angina, significant valvular disease, or cardiomyopathy within 1 year of screening.
•8. History of cardiac arrhythmias, second or third-degree AV block.
•9. History of seizures, schizophrenia, or bipolar disorder.
•10. Other condition or clinically important abnormality on vital signs, physical examination, neurologic examination, laboratory results or electrocardiogram (ECG) examination that could compromise the study efficacy interpretation or safety of the subject.
+5 more criteria

Locations (1)

Puerto Rico

San Juan, Puerto Rico

Key Dates

Start Date

January 11, 2021

Primary Completion Date

June 20, 2021

Completion Date

June 20, 2021

Last Updated

September 16, 2022

Enrollment

ACTUAL participants

Conditions

Dementia of Alzheimer Type

Interventions

IGC AD1

DRUG

Placebo

DRUG

Adaptation of the Uniform Data Set for Telematic Administration

NCT05785910

Dementia, MildDementia of Alzheimer Type

View study

COMPLETED

Couples Lived Experience

NCT04863495

Alzheimer DiseaseDementia of Alzheimer Type

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 16, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

Inclusion Criteria

Exclusion Criteria

Adaptation of the Uniform Data Set for Telematic Administration

Couples Lived Experience

THE EFFECT OF REMOTE NURSING INTERVENTIONS BASED ON THE EMPOWERMENT PROCESS MODEL ON PEOPLE WITH DEMENTIA AND THEIR FAMILY CAREGIVERS

DMB-I in the Treatment of Alzheimer Type Dementia

Prevalence of Alzheimer's Disease Pathology in the Community

An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions